Related Experiment Video

Updated: Jun 16, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Belzutifan in Europe: A New Targeted Therapy for Clear Cell Renal Cancer

Catherine Graham1, Laurence Albiges2, Marc-Oliver Grimm3

  • 1Barts Cancer Institute, London, UK.

European Urology
|May 17, 2025
PubMed

Insights

Belzutifan is now approved by the European Medicines Agency for advanced renal cell carcinoma. This well-tolerated drug provides an effective treatment option for patients with advanced disease.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is a significant cause of cancer-related mortality.
  • Effective third- and fourth-line treatment options for advanced RCC are limited.

Discussion:

  • Belzutifan has received European Medicines Agency marketing authorisation for advanced renal cell carcinoma.
  • It represents a well-tolerated and effective therapeutic option for patients refractory to prior treatments.

Key Insights:

  • Belzutifan offers a new treatment avenue for patients with advanced renal cell carcinoma.
  • The drug demonstrates a favorable tolerability profile.

Outlook:

  • Further clinical investigations are planned to evaluate belzutifan in earlier stages of renal cell carcinoma.
  • This may expand its utility in the management of kidney cancer.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K